Soleno Therapeutics, Inc.
SLNO
$73.64
$0.380.52%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 801.04% | 1,382.73% | 243.61% | 196.85% | 72.36% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 358.25% | 747.51% | 179.55% | 182.42% | 106.52% |
| Operating Income | -358.25% | -747.51% | -179.55% | -182.42% | -106.52% |
| Income Before Tax | -395.59% | -605.42% | -157.86% | -156.08% | -105.91% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -395.59% | -605.42% | -157.86% | -156.08% | -105.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -395.59% | -605.42% | -157.86% | -156.08% | -105.91% |
| EBIT | -358.25% | -747.51% | -179.55% | -182.42% | -106.52% |
| EBITDA | -372.33% | -788.68% | -190.72% | -194.06% | -115.58% |
| EPS Basic | -288.57% | -92.64% | 30.43% | 33.18% | 43.56% |
| Normalized Basic EPS | -327.13% | -110.21% | 33.16% | 32.01% | 54.01% |
| EPS Diluted | -288.57% | -92.64% | 29.90% | 33.18% | 43.56% |
| Normalized Diluted EPS | -327.13% | -110.21% | 33.16% | 32.01% | 54.01% |
| Average Basic Shares Outstanding | 27.53% | 266.18% | 270.62% | 283.26% | 264.84% |
| Average Diluted Shares Outstanding | 27.53% | 266.18% | 270.62% | 283.26% | 264.84% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |